Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
Status:
Completed
Trial end date:
2019-11-26
Target enrollment:
Participant gender:
Summary
This clinical trial aims at preventing visual dysfunction and optic nerve degeneration
associated with autoimmune optic neuritis by systemic i.v. administration of 33.000 IU
erythropoietin over 3 days. The primary objective is to determine the efficacy of
erythropoietin compared to placebo given as add-on to methylprednisolone as assessed by
measurements of retinal nerve fibre layer thickness and low contrast visual acuity 6 months
after acute optic neuritis.